Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2
The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increase...
Saved in:
Published in | Frontiers in immunology Vol. 13; p. 938556 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
20.09.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2022.938556 |
Cover
Loading…
Abstract | The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.New onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.MethodsNew onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.The levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.ResultsThe levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.Increased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.ConclusionIncreased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation. |
---|---|
AbstractList | BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.MethodsNew onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.ResultsThe levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.ConclusionIncreased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation. The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been fully clarified. Many studies have found that the level of soluble interleukin 2 receptor α (sIL-2Rα) in SLE patients is significantly increased. Considering the fact that sIL-2Rα has the ability to bind IL-2, we want to know whether the increased sIL-2Rα has some impact on the level and function of IL-2 in SLE patients.New onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.MethodsNew onset SLE patients, treated SLE patients and healthy volunteers were recruited. The levels of serum IL-2, IL-2 mRNA in CD3+ T cells and serum sIL-2Rα were detected and compared in these subjects. Two mixed solid-phase sandwich ELISA system were designed to measure exclusively the heterodimers complex of sIL-2Rα/IL-2. The sera from SLE patients were pretreated with or without immune complex dissociation solution and detected for IL-2 levels. IL-2 standard or serum from HCs were used to co-incubate with recombinant sIL-2Rα or serum samples with high levels of sIL-2Rα and detected for IL-2 levels by ELISA. The inhibitory effect of sIL-2Rα on IL-2 biological activity was investigated by CTLL-2 cell proliferation assay. The frequencies and absolute counts of Treg cells were detected by flow cytometry before and after the addition of recombinant sIL-2Rα.The levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.ResultsThe levels of serum IL-2 in SLE patients were significantly decreased and negatively correlated with SLEDAI. However, there was no significant difference in IL-2 mRNA levels in CD3+ T cells between SLE patients and healthy controls. The levels of serum sIL-2Rα in SLE patients were significantly increased, positively correlated with the SLEDAI and negatively correlated with the levels of serum IL-2. sIL-2Rα was shown to bind to IL-2 to form immune complex, resulting in false reduction in the detection level of serum IL-2 and significant decrease in biological activity of IL-2. The increase of sIL-2Rα was demonstrated to be one of the important mechanisms for the obstruction of Treg cells differentiation in SLE patients.Increased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation.ConclusionIncreased serum sIL-2Rα can bind to IL-2, leading to obstruction of IL-2 activity and Treg cells differentiation. |
Author | Xu, Shumin Zhang, Lu Li, Junming Yu, Shujiao Huang, Zikun Luo, Qing Guo, Yang Rao, Yuting Long, Dan |
AuthorAffiliation | Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University , Nanchang , China |
AuthorAffiliation_xml | – name: Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University , Nanchang , China |
Author_xml | – sequence: 1 givenname: Dan surname: Long fullname: Long, Dan – sequence: 2 givenname: Shujiao surname: Yu fullname: Yu, Shujiao – sequence: 3 givenname: Lu surname: Zhang fullname: Zhang, Lu – sequence: 4 givenname: Yang surname: Guo fullname: Guo, Yang – sequence: 5 givenname: Shumin surname: Xu fullname: Xu, Shumin – sequence: 6 givenname: Yuting surname: Rao fullname: Rao, Yuting – sequence: 7 givenname: Zikun surname: Huang fullname: Huang, Zikun – sequence: 8 givenname: Qing surname: Luo fullname: Luo, Qing – sequence: 9 givenname: Junming surname: Li fullname: Li, Junming |
BookMark | eNp1ks1qFTEUxwepYK19AHdZuplrvjPZCFKqXrgg1LoOmUwypmSSazJT8AV8H1_EZzJzp0IrmE2S8z_ndz44L5uzmKJtmtcI7gjp5Fvnp2nZYYjxTpKOMf6sOUec05ZgTM8evV80l6XcwXqoJISw8-bnPppsdbEDKPtDi29-_wLB6qGAOYHUlzkvZvYpguTAqoPep5BGb3QAbombpuMAbrMdgbEhFDB452y2cfb6JPsIvhyuwbH-qrGAe68rJg4-jmuWFfuqee50KPby4b5ovn64vr361B4-f9xfvT-0hlI8t6K3WCImDHS87xg1FBHhekiw4JAwaWpiIVgvISaCSEuJNohLiSmrrqYjF81-4w5J36lj9pPOP1TSXp0MKY9K59mbYJWjGCMtJeQIUd1ZDbUwVko-9I4zTivr3cY6Lv1kB1N7yzo8gT5Vov-mxnSvJCOId7gC3jwAcvq-2DKryZd1hDratBSFBSa1WQLXusXmanIqJVunjJ9P061kHxSCat0EddoEtW6C2jahRqJ_Iv8W-P-YPytQupA |
CitedBy_id | crossref_primary_10_1097_MD_0000000000041124 crossref_primary_10_3897_pharmacia_72_e132051 crossref_primary_10_1002_eji_202451298 crossref_primary_10_1007_s12026_024_09533_1 crossref_primary_10_5496_wjmg_v11_i3_28 crossref_primary_10_1016_j_autrev_2023_103270 crossref_primary_10_3389_fimmu_2023_1305590 crossref_primary_10_1016_j_phrs_2025_107658 |
Cites_doi | 10.3390/molecules22010030 10.1371/journal.pone.0047748 10.4049/jimmunol.130.6.2651 10.1172/JCI110579 10.1182/blood-2011-03-340885 10.1002/art.40014 10.1056/NEJMoa1105143 10.1002/eji.200425274 10.1111/j.0300-9475.2004.01370.x 10.1056/NEJMra1100359 10.4049/jimmunol.178.4.2579 10.1038/nri3156 10.1038/nrrheum.2016.173 10.1016/j.clim.2020.108515 10.1111/j.1365-2249.2007.03464.x 10.1146/annurev.immunol.26.021607.090357 10.1073/pnas.0903158107 10.3960/jslrt.54.49 10.1038/nri1435 10.1016/j.intimp.2020.106296 10.1038/ni1263 10.1038/nm.4148 10.4049/jimmunol.135.4.2865 10.3389/fimmu.2021.648408 10.1038/s41584-018-0133-2 10.1002/art.41457 10.1111/j.1472-8206.2005.00342.x 10.1615/CritRevImmunol.2018025213 10.1038/nrrheum.2017.201 10.1016/j.jim.2014.01.008 10.1084/jem.20041982 10.1002/art.1780350606 10.1038/nrrheum.2017.70 10.1002/art.1780400928 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li. Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li |
Copyright_xml | – notice: Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li. – notice: Copyright © 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li 2022 Long, Yu, Zhang, Guo, Xu, Rao, Huang, Luo and Li |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fimmu.2022.938556 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_f4221a9906114a8ea0a7ce996dbf6564 PMC9531682 10_3389_fimmu_2022_938556 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 5PM |
ID | FETCH-LOGICAL-c442t-7be29157c0f6b854c4137fb032760359cffe775b9023739e43ac1699245c41c83 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:27:12 EDT 2025 Thu Aug 21 18:39:57 EDT 2025 Fri Jul 11 03:40:57 EDT 2025 Thu Apr 24 22:58:11 EDT 2025 Tue Jul 01 02:11:26 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c442t-7be29157c0f6b854c4137fb032760359cffe775b9023739e43ac1699245c41c83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: José Carlos Crispín, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico Reviewed by: Erwan Mortier, Centre National de la Recherche Scientifique (CNRS), France; Garth E. Ringheim, Eisai, United States This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.938556 |
PQID | 2723157308 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f4221a9906114a8ea0a7ce996dbf6564 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9531682 proquest_miscellaneous_2723157308 crossref_citationtrail_10_3389_fimmu_2022_938556 crossref_primary_10_3389_fimmu_2022_938556 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-09-20 |
PublicationDateYYYYMMDD | 2022-09-20 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-20 day: 20 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in immunology |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Crispin (B4) 2017; 37 Lotze (B30) 1985; 135 Sakai (B34) 2014; 54 Russell (B37) 2012; 7 Fontenot (B23) 2005; 6 Humrich (B11) 2010; 107 El Houda Agueznay (B36) 2007; 150 Boyman (B25) 2012; 12 Liu (B5) 2004; 59 Yang Rong (B20) 2012; 28 Hochberg (B18) 1997; 40 Alcocer-Varela (B27) 1982; 69 Comte (B31) 2017; 69 Damoiseaux (B15) 2020; 218 He (B28) 2016; 22 Graßoff (B14) 2021; 12 Sheu (B35) 2001; 61 Setoguchi (B24) 2005; 201 Nishide (B1) 2018; 14 Saadoun (B29) 2011; 365 Orozco (B32) 2020; 81 Hao (B10) 2021; 73 Malek (B7) 2008; 26 Li (B13) 2017; 13 de la Rosa (B8) 2004; 34 Gatto (B2) 2019; 15 Linker-Israeli (B26) 1983; 130 Tsokos (B3) 2011; 365 Malek (B9) 2004; 4 Valencia (B6) 2007; 178 Yang (B17) 2011; 118 Peraino (B33) 2014; 405 El-Shafey (B16) 2008; 2 Yusup (B21) 2005; 19 Bombardier (B19) 1992; 35 Humrich (B12) 2016; 12 Wu (B22) 2016; 22 |
References_xml | – volume: 22 year: 2016 ident: B22 article-title: Dysregulation of cell death and its epigenetic mechanisms in systemic lupus erythematosus publication-title: Molecules doi: 10.3390/molecules22010030 – volume: 7 year: 2012 ident: B37 article-title: Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice publication-title: PloS One doi: 10.1371/journal.pone.0047748 – volume: 130 year: 1983 ident: B26 article-title: Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE) publication-title: J Immunol doi: 10.4049/jimmunol.130.6.2651 – volume: 69 year: 1982 ident: B27 article-title: Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus publication-title: J Clin Invest doi: 10.1172/JCI110579 – volume: 118 year: 2011 ident: B17 article-title: Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular b-cell non-Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2011-03-340885 – volume: 69 year: 2017 ident: B31 article-title: Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2 publication-title: Arthritis Rheumatol doi: 10.1002/art.40014 – volume: 365 year: 2011 ident: B29 article-title: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis publication-title: N Engl J Med doi: 10.1056/NEJMoa1105143 – volume: 34 year: 2004 ident: B8 article-title: Interleukin-2 is essential for CD4+CD25+ regulatory T cell function publication-title: Eur J Immunol doi: 10.1002/eji.200425274 – volume: 59 start-page: 198 year: 2004 ident: B5 article-title: Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus publication-title: Scand J Immunol doi: 10.1111/j.0300-9475.2004.01370.x – volume: 365 year: 2011 ident: B3 article-title: Systemic lupus erythematosus publication-title: N Engl J Med doi: 10.1056/NEJMra1100359 – volume: 178 year: 2007 ident: B6 article-title: Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus publication-title: J Immunol doi: 10.4049/jimmunol.178.4.2579 – volume: 12 year: 2012 ident: B25 article-title: The role of interleukin-2 during homeostasis and activation of the immune system publication-title: Nat Rev Immunol doi: 10.1038/nri3156 – volume: 12 year: 2016 ident: B12 article-title: Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2016.173 – volume: 218 start-page: 108515 year: 2020 ident: B15 article-title: The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor publication-title: Clin Immunol doi: 10.1016/j.clim.2020.108515 – volume: 150 year: 2007 ident: B36 article-title: Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: Prognostic value and analysis of their relationships publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2007.03464.x – volume: 26 year: 2008 ident: B7 article-title: The biology of interleukin-2 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090357 – volume: 107 year: 2010 ident: B11 article-title: Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus publication-title: Proc Natl Acad Sci U.S.A. doi: 10.1073/pnas.0903158107 – volume: 2 year: 2008 ident: B16 article-title: Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus publication-title: Iran J Kidney Dis – volume: 54 start-page: 49 year: 2014 ident: B34 article-title: The role of tumor-associated macrophages on serum soluble IL-2R levels in b-cell lymphomas publication-title: J Clin Exp Hematop doi: 10.3960/jslrt.54.49 – volume: 4 year: 2004 ident: B9 article-title: Tolerance, not immunity, crucially depends on IL-2 publication-title: Nat Rev Immunol doi: 10.1038/nri1435 – volume: 28 year: 2012 ident: B20 article-title: Study on immune complex dissociating agent and its application in HCV antigen detection publication-title: J Immunol – volume: 81 start-page: 106296 year: 2020 ident: B32 article-title: Interleukin-2 as immunotherapeutic in the autoimmune diseases publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106296 – volume: 6 year: 2005 ident: B23 article-title: A function for interleukin 2 in Foxp3-expressing regulatory T cells publication-title: Nat Immunol doi: 10.1038/ni1263 – volume: 22 year: 2016 ident: B28 article-title: Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus publication-title: Nat Med doi: 10.1038/nm.4148 – volume: 135 year: 1985 ident: B30 article-title: In vivo administration of purified human interleukin 2. II. half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2 publication-title: J Immunol doi: 10.4049/jimmunol.135.4.2865 – volume: 12 year: 2021 ident: B14 article-title: Low-dose IL-2 therapy in autoimmune and rheumatic diseases publication-title: Front Immunol doi: 10.3389/fimmu.2021.648408 – volume: 15 start-page: 30 year: 2019 ident: B2 article-title: New therapeutic strategies in systemic lupus erythematosus management publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-018-0133-2 – volume: 73 year: 2021 ident: B10 article-title: Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus publication-title: Arthritis Rheumatol doi: 10.1002/art.41457 – volume: 19 year: 2005 ident: B21 article-title: Cytotoxicity of abnormal savda munziq aqueous extract in human hepatoma (HepG2) cells publication-title: Fundam Clin Pharmacol doi: 10.1111/j.1472-8206.2005.00342.x – volume: 37 start-page: 39 year: 2017 ident: B4 article-title: SLE-associated defects promote altered T cell function publication-title: Crit Rev Immunol doi: 10.1615/CritRevImmunol.2018025213 – volume: 14 start-page: 19 year: 2018 ident: B1 article-title: The role of semaphorins in immune responses and autoimmune rheumatic diseases publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2017.201 – volume: 405 start-page: 57 year: 2014 ident: B33 article-title: Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells publication-title: J Immunol Methods doi: 10.1016/j.jim.2014.01.008 – volume: 201 year: 2005 ident: B24 article-title: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization publication-title: J Exp Med doi: 10.1084/jem.20041982 – volume: 35 year: 1992 ident: B19 article-title: Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE publication-title: Arthritis Rheum doi: 10.1002/art.1780350606 – volume: 61 year: 2001 ident: B35 article-title: A novel role of metalloproteinase in cancer-mediated immunosuppression publication-title: Cancer Res – volume: 13 start-page: 386 year: 2017 ident: B13 article-title: The rise of IL-2 therapy - a picture beyond treg cells publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2017.70 – volume: 40 start-page: 1725 year: 1997 ident: B18 article-title: Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis Rheum doi: 10.1002/art.1780400928 |
SSID | ssj0000493335 |
Score | 2.3699608 |
Snippet | The decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have not been... BackgroundThe decrease of IL-2 level is believed to play an important role in the disease occurrence and development of SLE, but the relevant mechanisms have... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 938556 |
SubjectTerms | IL-2 immune complex Immunology sIL-2R systemic lupus erythematosus Treg cells |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELaqSkhcKkpBXf40SJwqhWb9E8dHQK1KVXHoj9SbZTsOLGoTRLaVeAHehxfhmZixs6vNBS5cY8dO_E083ySTbxh7w70LUaHxKtwhC-lELDx6naJtPLKPxvjQpGyLT9XJlTy9Vtcbpb4oJyzLA-eFO2wl53OHe2aFzN3V0ZVOh4gsvfEtcpGkBIo-byOY-pp5rxBC5c-YGIWZw3Zxe3uH8SDnb42oFRWs3nBESa9_QjKnKZIbPuf4EdsZySK8yxe5y7Zi95g9yOUjf-yxn_hwU055bGD4eFbw89-_4AYxG2DZQ-_X0rDQt0DtkBWXCBYgf5baXNfA5ff4GegV_gCrginLDBksOrg4O4JRfnWA-4XDYdKvMDQLDfuEXR0fXX44Kca6CkWQki8L7SM3c6VD2Va-VjIgTLr1peC6IkW_gBNprbxBf66FiVK4MK8MRmoKu4ZaPGXbXd_FfQay8lq1pXZlU8ngownRudI7xY3E7WI-Y-VqkW0YRcep9sWNxeCDcLEJF0u42IzLjB2sT_mWFTf-1vk9IbfuSGLZ6QCakB1NyP7LhGbs9Qp3iw8XLbfrYn83WK6R_ircBOsZ0xODmMw4bekWX5JMt1FUFIw_-x-X-Jw9pLumRBVevmDbaEDxJbKhpX-VDP8P6JUJcQ priority: 102 providerName: Directory of Open Access Journals |
Title | Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2 |
URI | https://www.proquest.com/docview/2723157308 https://pubmed.ncbi.nlm.nih.gov/PMC9531682 https://doaj.org/article/f4221a9906114a8ea0a7ce996dbf6564 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB6VIiQuiF-x_FRG4oSUkjj-SQ6oAtRSUOEAXWlvlu047aJtApstal-A9-FFeCZmnOyKSBUSl0iJHVuZb-yZSSbfADznzvogUXkl7pCJsHlIHFqdpK4ceh9V6XwVsy0-qcOp-DCTsy1Yl7caBNhdGdpRPanpcrF78f1yDxf8K4o40d6-rOdnZ-cY6nG-W-aFlOoaXEfDpEjJPw7e_tfeGc7zWHIzU0okqMqi_8559SgjSxUJ_Ude6DiH8i-jdHAbbg3eJHvdw38HtkJzF2709SUv78FPXP2UdB4q1r0_Svjn37_YAkHt2Kplrdtwx7K2ZtTOekomwo2RwYtttqnY8TKcMHrH37F1RZVVjymbN-zL0T4b-Fk79mNucZj4rwzNQsPeh-nB_vHbw2QovJB4Ifgq0S7wMpPap7VyhRQecdS1S3OuFVH-eZxIa-lKNPg6L4PIrUdxYygnsasv8gew3bRNeAhMKKdlnWqbVkp4F0ofrE2dlbwUuJ9kE0jXQjZ-YCWn4hgLg9EJ4WIiLoZwMT0uE3ixueVbT8nxr85vCLlNR2LTjhfa5YkZFqepBeeZRbusMDq0RbCp1T5gJFi5Gv1dMYFna9wNrj4St21Ce94ZrtE_lrhLFhPQI4UYzThuaeankce7lFQ1jD_6n-d5DDfpjDJWePoEtlFRwlN0i1ZuJ75OwOO7WbYTFf8PgIoNPQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+sIL-2R%CE%B1+leads+to+obstruction+of+IL-2+biological+function+and+Treg+cells+differentiation+in+SLE+patients+via+binding+to+IL-2&rft.jtitle=Frontiers+in+immunology&rft.au=Long%2C+Dan&rft.au=Yu%2C+Shujiao&rft.au=Zhang%2C+Lu&rft.au=Guo%2C+Yang&rft.date=2022-09-20&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.938556&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_938556 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |